Hoba Therapeutics, founded in 2016 by Novo Holdings and the Export and Investment Fund of Denmark (EIFO), is a Danish biotech company dedicated to developing novel therapeutic proteins for patients living with chronic neuropathic pain and hearing loss. The lead asset, HB-086, a non opioid compound, with a unique mode of action, targets the treatment of chronic neuropathic pain conditions. Neuropathic pain represents a significant unmet medical need, affecting more than 400 million patients worldwide.

Indaco has led, together with Medical Incubator Japan, a USD25M series A investment round, including Novo Holdings, EIR Ventures, EIFO and European Innovation Council Fund, that will enable Hoba Therapeutics to advance HB-086 through late pre-clinical development to the completion of Phase 1 clinical studies in patients for painful Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Indaco Bio Fund has invested into Hoba Therapeutics in December 2023.